Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis
- PMID: 20074478
- DOI: 10.1177/039463200902200430
Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis
Abstract
The aim of this study is to determine the effects of a combination treatment with etanercept and spa rehabilitation versus etanercept alone on function, disability and quality of life in a group of patients with active ankylosing spondylitis (AS). Sixty patients with AS underwent etanercept as suggested by ASAS/EULAR recommendations. As the clinical and laboratory conditions improved, 30 patients accepted the proposal of coupling the medical therapy with a 7-day rehabilitation program in a thermal baths centre; the remaining 30 subjects continued to take the biologic agent alone. The comparisons between the 2 groups were made after 3 and 6 months. The primary outcome was an improvement in BASFI. The secondary outcome was an improvement in the visual analogic scale of EuroQol (EQ-5Dvas). After 6 months a statistically significant improvement in BASFI (p < 0.05) and EQ-5DVAS (p < 0.05) scores was observed in both groups. The mean change in EQ-5DVAS value showed a statistically significant difference in favour of the combination therapy group versus the monotherapy group (22 vs 32, p < 0.05). A therapeutic regimen combining etanercept with an intensive rehabilitation program contributes to disability reduction and ameliorates quality of life for AS patients.
Similar articles
-
Effects of a combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: a pilot study.J Rheumatol. 2006 Oct;33(10):2029-34. J Rheumatol. 2006. PMID: 17014018 Clinical Trial.
-
The effects of combined spa therapy and rehabilitation on patients with ankylosing spondylitis being treated with TNF inhibitors.Rheumatol Int. 2013 Jan;33(1):241-5. doi: 10.1007/s00296-011-2147-9. Epub 2011 Sep 27. Rheumatol Int. 2013. PMID: 21947374 Clinical Trial.
-
Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.Rheumatology (Oxford). 2007 Jun;46(6):999-1004. doi: 10.1093/rheumatology/kem069. Epub 2007 Mar 27. Rheumatology (Oxford). 2007. PMID: 17389658 Clinical Trial.
-
[Anti-TNF alfa therapy in ankylosing spondylitis].Acta Med Port. 2006 Mar-Apr;19(2):141-50. Epub 2006 Aug 18. Acta Med Port. 2006. PMID: 17187716 Review. Portuguese.
-
Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.Am J Med Sci. 2013 Dec;346(6):455-61. doi: 10.1097/MAJ.0b013e3182926a23. Am J Med Sci. 2013. PMID: 23715113 Review.
Cited by
-
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.Ann Rheum Dis. 2011 Jun;70(6):896-904. doi: 10.1136/ard.2011.151027. Ann Rheum Dis. 2011. PMID: 21540199 Free PMC article.
-
Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.RMD Open. 2017 Jan 27;3(1):e000397. doi: 10.1136/rmdopen-2016-000397. eCollection 2017. RMD Open. 2017. PMID: 28176966 Free PMC article.
-
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.7 Rehabilitation].Z Rheumatol. 2014 Sep;73 Suppl 2:101-3. doi: 10.1007/s00393-014-1445-5. Z Rheumatol. 2014. PMID: 25181980 German. No abstract available.
-
Concurrent Intervention With Exercises and Stabilized Tumor Necrosis Factor Inhibitor Therapy Reduced the Disease Activity in Patients With Ankylosing Spondylitis: A Meta-Analysis.Medicine (Baltimore). 2015 Dec;94(50):e2254. doi: 10.1097/MD.0000000000002254. Medicine (Baltimore). 2015. PMID: 26683943 Free PMC article. Review.
-
[ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area].Z Rheumatol. 2013 Feb;72(1):71-80. doi: 10.1007/s00393-012-1071-z. Z Rheumatol. 2013. PMID: 23223873 German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials